• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players - Product Image

Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players

  • Published: April 2013
  • Region: Japan
  • 97 Pages
  • GBI Research

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Daiichi Sankyo Ltd.
  • Eisia Ltd.
  • Otsuka Holdings Ltd.
  • MORE

GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.

Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the increase of drug prices. In addition, the gradual increase in market share and competition from generics has depressed market value and will continue to do so as government policy promotes their use.

However, easing of regulatory guidelines, an aging population and a strong product pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although the increasing READ MORE >

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction

3 Market Overview
3.1 Introduction
3.2 Economic Landscape
3.3 Economic Indicators
3.3.1 Gross Domestic Product
3.3.2 GDP Composition by Sector
3.3.3 Consumer Price Index
3.3.4 Unemployment
3.3.5 Exchange Rate
3.3.6 Foreign Direct Investment
3.3.7 Trade Balance
3.3.8 Value of Exports/Imports
3.3.9 Exports and Imports Forecast
3.3.10 Trading Partners
3.3.11 Government Debt
3.3.12 Gross National Income
3.3.13 Gross National Savings
3.3.14 Labor Force
3.3.15 Employment
3.3.16 Current Account Balance
3.3.17 Foreign Exchange Reserves
3.4 Demographic Analysis
3.4.1 Population
3.4.2 Population Distribution
3.4.3 Urban-Rural Share
3.5 Healthcare
3.5.1 Healthcare Expenditure
3.5.2 Public and Private Expenditure
3.5.3 Healthcare Infrastructure
3.5.4 Alcohol Consumption
3.5.5 Tobacco Consumption
3.5.6 Obesity
3.5.7 Life Expectancy
3.5.8 Leading Causes of Death
3.5.9 Pharmaceutical Expenditure
3.5.10 Insurance and Reimbursement
3.5.11 Reimbursement Process
3.6 Market Segments
3.6.1 Generics
3.6.2 Over-the-Counter Drugs

4 Industry Characteristics
4.1 Introduction
4.2 Pricing Policy
4.2.1 Reimbursement Prices for New Drugs
4.3 Regulatory Landscape
4.3.1 Pharmaceutical and Food Safety Bureau
4.3.2 Pharmaceutical and Medical Devices Agency
4.3.3 New Drug Approval Process
4.3.4 Drug Manufacture
4.3.5 Clinical Trials – Basic Requirements
4.3.6 Advertising
4.3.7 Licensing
4.3.8 Orphan Drugs
4.4 Pharmaceutical Supply Chain
4.4.1 Leading Companies

5 Competitive Landscape
5.1 Introduction
5.2 Major Domestic Companies
5.2.1 Major Players by Revenue
5.2.2 Takeda
5.2.3 Product Portfolio
5.2.4 Research and Development
5.2.5 Otsuka
5.2.6 Product Portfolio
5.2.7 Research and Development
5.2.8 Astellas
5.2.9 Product Portfolio
5.2.10 Research and Development
5.2.11 Daiichi Sankyo
5.2.12 Product Portfolio
5.2.13 Research and Development
5.2.14 Eisai
5.2.15 Research and Development
5.3 Major Foreign Players
5.4 Acquisitions and Collaboration
5.4.1 M&A
5.4.2 Licensing Agreements and Co-development Deals

6 Drivers and Barriers
6.1 Drivers
6.1.1 World-Leading Life Expectancy – Increased Disease Burden
6.1.2 Deregulation – Easing of Regulatory Guidelines
6.1.3 Government Initiatives to Prevent Lifestyle Diseases
6.1.4 Continued Growth of the Generics Market
6.2 Barriers
6.2.1 Time Lag in Drug Approval Process
6.2.2 Political Instability
6.2.3 High Cost of Clinical Trials
6.2.4 High Value of the Yen

7 Japan Pharmaceutical Market Outlook – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 Research Methodology
7.5 Coverage
7.6 Secondary Research
7.7 Competitive Landscape
7.7.1 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

1.1 List of Tables

Table 1: Pharmaceutical Market, Japan, Health Insurance, 1922–2008
Table 2: Pharmaceutical Market, Japan, Insurance and Reimbursement, 2009
Table 3: Pharmaceutical Market, Japan, Premium Rates and Requirements, 2012
Table 4: Pharmaceutical Market, Japan, Pharmaceutical Supply Chain, Leading Companies, Revenue ($bn), 2012
Table 5: Takeda, Japan, Major Product Portfolio, Revenue ($bn), 2011
Table 6: Takeda, Japan, Product Pipeline, 2012
Table 7: Otsuka, Japan, Major Product Portfolio, Revenue ($m), 2010
Table 8: Otsuka, Japan, Product Pipeline, 2012
Table 9: Astellas, Japan, Major Product Portfolio, Revenue ($m), 2011
Table 10: Astellas, Japan, Product Pipeline, 2011
Table 11: Daiichi Sankyo, Japan, R&D Pipeline, Revenue ($bn), 2012
Table 12: Daiichi Sankyo, Japan, R&D Pipeline, 2012
Table 13: Eisai, Japan, Major Product Portfolio, Revenue ($bn), 2011
Table 14: Eisai, Japan, Product Pipeline, 2012
Table 15: Pharmaceutical Market, Japan, Licensing Agreements by Company, 2005–2012

1.2 List of Figures

Figure 1: Pharmaceutical Market, Japan, Gross Domestic Product ($tn), 2005–2017
Figure 2: Pharmaceutical Market, Japan, Gross Domestic Product Growth (%), 2005–2017
Figure 3: Pharmaceutical Market, Japan, Gross Domestic Product Per Capita ($), 2005–2017
Figure 4: Pharmaceutical Market, Japan, Gross Domestic Product by Sector (%), 2011
Figure 5: Pharmaceutical Market, Japan, Annual Consumer Price Index, 2005–2017
Figure 6: Pharmaceutical Market, Japan, Average Consumer Price Change (%), 2005–2017
Figure 7: Pharmaceutical Market, Japan, Unemployment (%), 2005–2017
Figure 8: Pharmaceutical Market, Japan, Youth Unemployment (%), 2005–2010
Figure 9: Pharmaceutical Market, Japan, Currency Exchange Rate (JPY/$), 2005–2011
Figure 10: Pharmaceutical Market, Japan, Foreign Direct Investment Outflows ($bn), 2005–2011
Figure 11: Pharmaceutical Market, Japan, Foreign Direct Investment Inflows ($bn), 2005–2011
Figure 12: Pharmaceutical Market, Japan, Trade Balance ($bn), 2005–2011
Figure 13: Pharmaceutical Market, Japan, Exports and Imports ($bn), 2005–2010
Figure 14: Pharmaceutical Market, Japan, Exports and Imports Forecast (%), 2010–2017
Figure 15: Pharmaceutical Market, Japan, Exports by Trading Partner (%), 2011
Figure 16: Pharmaceutical Market, Japan, General Government Gross Debt (% of GDP), 2005–2017
Figure 17: Pharmaceutical Market, Japan, Gross National Income (PPP $tn), 2005–2011
Figure 18: Pharmaceutical Market, Japan, Gross National Income Growth (%), 2005–2010
Figure 19: Pharmaceutical Market, Japan, Gross National Income Per Capita (PPP $), 2005–2011
Figure 20: Pharmaceutical Market, Japan, Gross National Savings (% of GDP), 2005–2017
Figure 21: Pharmaceutical Market, Japan, Labor Force (Millions), 2005–2011
Figure 22: Pharmaceutical Market, Japan, Labor Force by Occupation (%), 2010
Figure 23: Pharmaceutical Market, Japan, Employment to Population Ratio, Age 15+ (%), 2005–2010
Figure 24: Pharmaceutical Market, Japan, Employment to Population Ratio by Gender, Age 15+ (%), 2005–2010
Figure 25: Pharmaceutical Market, Japan, Current Account Balance ($bn), 2005–2011
Figure 26: Pharmaceutical Market, Japan, Foreign Exchange Reserves ($bn), 2005–2011
Figure 27: Pharmaceutical Market, Japan, Crude Birth and Death Rate (Per 1,000 Population), 2005–2010
Figure 28: Pharmaceutical Market, Japan, Population by Age Group (%), 2000–2020
Figure 29: Pharmaceutical Market, Japan, Urban-Rural Share (%), 2005–2010
Figure 30: Pharmaceutical Market, Japan, Healthcare Expenditure, Percentage of GDP (%), 2005–2010
Figure 31: Pharmaceutical Market, Japan, Healthcare Expenditure Per Capita ($), 2005–2010
Figure 32: Pharmaceutical Market, Japan, Public and Private Expenditure (%), 2005–2010
Figure 33: Pharmaceutical Market, Japan, Expenditure as Percentage of Government Expenditure (%), 2005–2010
Figure 34: Pharmaceutical Market, Japan, Out-of-Pocket Expenditure (%), 2005–2010
Figure 35: Pharmaceutical Market, Japan, Hospital Beds (Per 1,000 Population), 2005–2010
Figure 36: Pharmaceutical Market, Japan, Physicians (Per 1,000 Population), 2002–2010
Figure 37: Pharmaceutical Market, Japan, Average Hospital Stay (Days), 2005–2010
Figure 38: Pharmaceutical Market, Japan, Alcohol Consumption (Liters Per Capita), 2005–2010
Figure 39: Pharmaceutical Market, Japan, Tobacco Consumption (%), 2005–2010
Figure 40: Pharmaceutical Market, Japan, Tobacco Consumption by Gender (%), 2005–2010
Figure 41: Pharmaceutical Market, Japan, Obesity (%), 2005–2010
Figure 42: Pharmaceutical Market, Japan, Life Expectancy at Birth (Years), 2005–2010
Figure 43: Pharmaceutical Market, Japan, Death Rate by Leading Causes (Per 100,000 Population), 2011
Figure 44: Pharmaceutical Market, Japan, Financial Source of Healthcare Insurance (%), 2008
Figure 45: Pharmaceutical Market, Japan, Generic Market, Volume and Value (%), 2005–2011
Figure 46: Pharmaceutical Market, Japan, Over-the-Counter Drugs, Revenue Forecast ($bn), 2008–2016
Figure 47: Pharmaceutical Market, Japan, Ministry of Health, Labor and Welfare, Structure, 2012
Figure 48: Pharmaceutical Market, Japan, Pharmaceutical and Food Safety Bureau, Structure, 2012
Figure 49: Pharmaceutical Market, Japan, Pharmaceutical and Medical Devices Agency, Structure, 2012
Figure 50: Pharmaceutical Market, Japan, New Drug Approval Process, 2012
Figure 51: Pharmaceutical Market, Japan, Pharmaceutical Supply Chain. 2012
Figure 52: Pharmaceutical Market, Japan, Major Domestic Companies, Revenue ($bn), 2012
Figure 53: Pharmaceutical Market, Japan, M&A, 2005–2012
Figure 54: Pharmaceutical Market, Japan, M&A Deals by Country, 2005–2012
Figure 55: Pharmaceutical Market, Japan, M&A, Aggregate Deal Value ($bn), 2005–2012
Figure 56: Pharmaceutical Market, Japan, Licensing Agreements, 2005–2012
Figure 57: Pharmaceutical Market, Japan, Co-development Deals, 2005–2012

- Astellas Pharma Inc.
- Daiichi Sankyo Ltd.
- Eisia Ltd.
- Otsuka Holdings Ltd.
- Takeda Pharmaceutical Ltd.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos